Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Weighted Average) (2017 - 2025)

Arcus Biosciences (RCUS) has 7 years of Shares Outstanding (Weighted Average) data on record, last reported at $107.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed N/A year-over-year to $107.4 million; the TTM value through Dec 2025 reached $107.4 million, changed N/A, while the annual FY2025 figure was $107.4 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $107.4 million in Q4 2025 per RCUS's latest filing, up from $103.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $107.4 million in Q4 2025 and bottomed at $69.3 million in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $83.3 million, with a median of $74.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 26.49% in 2021, then grew 2.24% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $69.3 million in 2021, then grew by 3.9% to $72.0 million in 2022, then rose by 2.78% to $74.0 million in 2023, then grew by 21.08% to $89.6 million in 2024, then increased by 19.87% to $107.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $107.4 million in Q4 2025, $103.7 million in Q3 2025, and $106.1 million in Q2 2025.